News | Breast Imaging | October 26, 2016

Four-year study comparing tomosynthesis to standard digital mammography will enroll 165,000 asymptomatic women in the United States and Canada

ECOG-ACRIN, TMIST, Tomosynthesis Mammography Imaging Screening Trial, site recruitment, RSNA 2016

October 26, 2016 — The Tomosynthesis Mammography Imaging Screening Trial (TMIST), the first large-scale breast cancer screening trial in nearly 25 years, has been approved for funding by the National Cancer Institute (NCI). The ECOG-ACRIN Cancer Research Group (ECOG- ACRIN) leading the trial is now recruiting medical facilities as it prepares to open the trial in mid-2017.

TMIST will enroll 165,000 asymptomatic women in the United States and Canada between the ages of 45 and 74 to compare the incidence of advanced cancers in those screened for four years with digital breast tomosynthesis versus standard digital mammography. The study aims to provide a modern basis for the continued use of mammography for breast cancer screening.

Interested medical imaging providers can attend one of two TMIST informational sessions while at the upcoming Radiological Society of North America (RSNA) annual meeting, Nov. 27-Dec. 3 in Chicago.

To participate in TMIST, a medical facility must be (1) located in the U.S. or Canada, (2) able to provide both imaging methods in the same location, and (3) a member of a research group in the NCI National Clinical Trials Network (NCTN), either directly or through the NCI Community Oncology Research Program (NCORP). TMIST will require nearly 100 sites, estimating that each will enroll about four to five women per day to reach the accrual goal in about three years.

TMIST image acquisition, storage and sharing will be carried out at the American College of Radiology (ACR) Center for Research and Innovation. Constantine A. Gatsonis, Ph.D., at the ECOG-ACRIN Biostatistics and Data Management Center at Brown University Center for Statistician Sciences, will lead the TMIST statistical analysis.

The NTCN research groups are the Alliance for Clinical Trials in Oncology, Canadian Cancer Clinical Trials Network, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG.

For more information: www.ecog-acrin.org


Related Content

News | Women's Health

June 23, 2025 — Susan G. Komen, the world’s leading breast cancer organization, recently announced it is awarding $10.8 ...

Time June 23, 2025
arrow
Feature | Women's Health | Christine Murray

In breast cancer detection, speed and accuracy are more than clinical goals – they can significantly increase chances ...

Time June 17, 2025
arrow
News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Imaging Software Development

May 27, 2025 — DeepLook Medical, a company advancing medical imaging through visual enhancement technology, recently ...

Time May 28, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
Subscribe Now